U.S. Carrier Screening Market Size Expected to reach $2.14 Billion by 2031 | CAGR of 14.4%

U.S. Carrier Screening Market Size Expected to reach $2.14 Billion by 2031 | CAGR of 14.4%

According to a new report published by Allied Market Research, titled, “U.S. carrier screening Market by Type, Technology and End User: Opportunity Analysis and Industry Forecast, 2022-2031, “The U.S. carrier screening market size was valued at $585.46 Million in 2021 and is projected to reach $2,147.24 Million by 2031, registering a CAGR of 14.4% from 2022 to 2031.” 

Carrier screening is a type of genetic testing that checks if a person who is pregnant (or intending to get pregnant) carries genes for specific genetic disorders. This test allows people to assess the risk of passing on certain genetic conditions to their children. It is a non-invasive test as it involves testing a sample of blood, saliva, or tissue from the inside of the cheek. There are two main types of carrier screening tests, molecular (analyzing the DNA-genetic code) and biochemical (measuring enzyme activity). Carrier screening for Tay-Sachs disease and Sandhoff disease involves a combination of both genetic and enzyme screening for the most sensitive results.

The key factors that drive the growth of the market are the increase in awareness among people about the early detection of genetic diseases such as cystic fibrosis, sickle cell anemia, Tay-Sachs disease, and various others.

Moreover, the increasing ailments of chronic diseases among the population have also led to an increase in demand for safe and effective carrier tests which propels the growth of the market. Furthermore, the surge in demand for personalized medicine and the strategies adopted by key players in the U.S. carrier screening market such as product launches, acquisition, and investments in R&D for advancement in carrier screening to strengthen their position in the market and sustain the competitive environment boosts the growth of the U.S. carrier screening market. 

In November 2022, Myriad Genetics, Inc. acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests, including the SneakPeek which is an early gender DNA test. SneakPeek reveals a baby’s gender at six weeks into pregnancy, the only at-home test to do so with 99% accuracy and the earliest method available. The acquisition strengthens Myriad Genetics’ portfolio of women’s health products, expanding access to personalized genetic tests during the reproductive stage of a woman’s life and beyond.

However, the lack of skilled professionals is the major barrier to the growth of the market. Emerging new cases of genetic diseases are anticipated to create lucrative opportunities during the forecast period owing to the rising awareness of carrier screening, and the rapid increase in the number of chronic diseases. 

On the basis of type, the U.S. carrier screening market is segmented into expanded carrier screening and targeted disease carrier screening. The expanded carrier screening segment is further divided into customized panel testing and predesigned panel testing. In 2021, the expanded carrier screening segment accounted for the largest share of the market. The dominance of this segment can be attributed to rising awareness about the importance of carrier screening tests by pregnant women for determining the chances or risk of a child inheriting genetic disorders from the parents, increasing the demand for expanded carrier screening. 

The targeted disease carrier screening segment is expected to witness considerable market growth during the forecast period, owing to an increase in the prevalence of fetal chromosomal abnormalities and genetic disorders and the rising demand for personalized medicines for targeted drug delivery.

On the basis of technology, the market is categorized into DNA sequencing, polymerase chain reaction, microarrays, and others. In 2021, the DNA sequencing segment accounted for the largest share of the market. The dominance of this segment can be attributed to the benefits offered by this technique including its precise accuracy is one of the main factors that define the utility of a genetic carrier testing workflow in a clinical laboratory boosts the growth of the U.S. carrier screening market. 

The polymerase chain reaction segment is anticipated to be the fastest growing segment during the forecast period, owing to the advantages offered by this technology such as it is quick and accurate in diagnosing infectious diseases and genetic changes.

By end user, the market is segmented into hospitals & clinics, reference laboratories, physician offices, and others. The hospitals & clinics segment exhibited the highest growth in 2021 and is anticipated to lead during the forecast period, owing to improving healthcare facilities, facilities for medical and surgical treatment as well as nursing care to patients, physical rehabilitation post surgeries, and the availability of advanced equipment are the key factors that drive the growth of the market in upcoming years.

The physician offices segment is anticipated to be the fastest growing segment during the forecast period, owing to the rise in the number of physician’s clinics and the rising demand of geneticists for the detection of genetic disorders which propels the growth of the market.

The key players that operate in the U.S. carrier screening market include Fulgent Genetics Inc., Invitae Corporation, Illumina Inc., PerkinElmer Inc., Myriad Genetics, Inc., Natera Inc., LabCorp, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Sema4. 

Key Findings Of The Study

• By type, the expanded carrier screening segment was the highest contributor to the U.S. carrier screening market in 2021.
• By technology, the DNA sequencing segment was the highest contributor to the U.S. carrier screening market in 2021.
• By end user, the physician office segment is projected to grow at a significant CAGR of 15.7% from 2022 to 2031.